Gamma-secretase inhibitors are a class of compounds that target the gamma-secretase enzyme complex, which plays a crucial role in the proteolytic processing of amyloid precursor protein (APP) and other substrates. The inhibition of this enzyme is of significant interest in the context of Alzheimer's disease, as it can reduce the production of amyloid-beta peptides, which aggregate to form plaques associated with the disease. The specific compound with CAS number 133407-83-7 is characterized by its ability to selectively inhibit gamma-secretase activity, thereby modulating the levels of amyloid-beta. These inhibitors often exhibit a complex structure that allows for interaction with the enzyme's active site or allosteric sites, influencing its function. Additionally, the pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are critical for determining the efficacy and safety profile of these compounds in therapeutic applications. Research continues to explore the balance between efficacy in reducing amyloid-beta levels and potential side effects due to the inhibition of other gamma-secretase substrates.

GAMMA-SECRETASE INHIBITOR

133407-83-7: Gamma-secretase inhibitors are a class of compounds that target the gamma-secretase enzyme complex, which plays a crucial role in the proteolytic processing of amyloid precursor protein (APP) and other substrates. The inhibition of this enzyme is of significant interest in the context of Alzheimer's disease, as it can reduce the production of amyloid-beta peptides, which aggregate to form plaques associated with the disease. The specific compound with CAS number 133407-83-7 is characterized by its ability to selectively inhibit gamma-secretase activity, thereby modulating the levels of amyloid-beta. These inhibitors often exhibit a complex structure that allows for interaction with the enzyme's active site or allosteric sites, influencing its function. Additionally, the pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are critical for determining the efficacy and safety profile of these compounds in therapeutic applications. Research continues to explore the balance between efficacy in reducing amyloid-beta levels and potential side effects due to the inhibition of other gamma-secretase substrates.

<p>Z-Leu-Leu-Nle (ZLL) is a small molecule that selectively inhibits the activity of the aspartyl protease, BACE1, which is an enzyme that cleaves amyloid precursor protein (APP) to produce amyloid beta peptides. The inhibition of this enzyme has been shown to be effective in preventing or delaying the onset of Alzheimer's disease. ZLL also inhibits estrogen receptor alpha and has antiestrogenic effects in breast cancer cells. This compound induces apoptosis by binding to apoptotic proteins, such as tumor necrosis factor receptor 1, Fas ligand, and TRAIL receptors. It also inhibits cell growth and induces chemoresistance in breast cancer cells.</p>

CAS 133407-83-7

GAMMA-SECRETASE INHIBITOR

Z-Leu-Leu-Nle-aldehyde

Ref: 3D-FL111080